RMD Articles, ResMed Inc. - From 06/19/24

The Zacks Medical – Products industry's revenues are expected to continue its growth trajectory on the back of the recovery in demand for...

ResMed (NYSE:RMD) has outperformed the market over the past 15 years by 4.44% on an annualized basis producing an average annual return of 17.24%. ...

Zimmer Biomet (NYSE: ZBH) and RevelAi Health accepted a multi-year co-marketing agreement to commercialize generative artificial intelligence-...

Haemonetics (NYSE: HAE) has been gaining from business growth within Plasma, Hospital and Hemostasis Management. Its new launches also aid growth. ...

Abbott (NYSE: ABT) announced that Lingo and Libre Rio, two of its glucose monitoring system, have received FDA clearance. Lingo and Libre Rio are b...

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year re...

ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 7.11% on an annualized basis producing an average annual return of 15.03%. ...

How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio a...

Haemonetics Corporation‘s (NYSE: HAE) shares have increased 10.8% year to date compared with the industry's rise of 6.1%. The Medical sec...

ResMed (NYSE:RMD) has outperformed the market over the past 10 years by 4.86% on an annualized basis producing an average annual return of 15.65%. ...